Summit of Whose Future? Girls Have the Answers: Leaders Must Listen
Young Women Activists Launch "What Girls Want," Demand World Leaders Put Girls at the Center of Summit of the Future NEW YORK, Sept. 21, 2024 /PRNewswire/ -- Today in New York, more than 50 young women from around the world – including Nobel Prize Laureate Malala Yousafzai – gathered to take government...
Gymera Reveal A Breakthrough in Smart Home Fitness and Elderly Wellness Solution at Hong Kong Global Sources Consumer Electronics Show 2024
SHENZHEN, China, Sept. 21, 2024 /PRNewswire/ -- In today's fast-paced world, maintaining health and vitality has become increasingly important, especially in home fitness and eldercare scenarios. Gymera proudly introduces the MA-001, a full-featured smart fitness mirror that perfectly integrates cutting-edge technology with home fitness. This innovative device provides personalized and efficient workouts for every family member, with a special...
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) has already been approved in China, Indonesia, Cambodia, and Thailand, benefiting around 80,000 patients SHANGHAI, Sept. 21, 2024 /PRNewswire/...
Ginseng Gives Back: Jung Kwan Jang Tesla Giveaway and Give a Gift of Health Initiative
- Celebrate Charity Day and Chuseok with JungKwanJang's Tesla Giveaway and Give a Gift of Health Initiative CERRITOS, Calif., Sept. 21, 2024 /PRNewswire/ -- Cerritos, CA - Korea Ginseng Corp. US (KGCUS) aka JungKwanJang is celebrating two significant occasions this September: the International Day of Charity and Chuseok, Korea's Thanksgiving. In honor...
European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare
KOTA KINABALU, Malaysia, Sept. 21, 2024 /PRNewswire/ -- European Wellness, a global leader in regenerative medicine and integrated healthcare, has inaugurated its latest and most advanced facility, the European Wellness New Premier Center, in Kota Kinabalu, Sabah. This landmark 60,000 square-foot center represents a significant leap forward for healthcare in Sabah and...
Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results
YANGZHOU, China, Sept. 21, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today reported its unaudited financial results for the six months ended June 30, 2024. All amounts below are in U.S....
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting
BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe,...
Kangpu Completed Bridging Clinical Study of KPG-818 in China
HEFEI, China, Sept. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China. The randomized, double-blind, placebo-controlled, and food effects (FE) study aimed to assess the safety and tolerability of...
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
SUZHOU, China, Sept. 20, 2024 /PRNewswire/ -- CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial. CD-001, the company's leading clinical candidate, is built on its proprietary Bispecific Fusion Protein (BsFP) platform. This potential therapy, designed to target PD-1 positive...
Global claims guidance leader EvolutionIQ joins as CALI’s inaugural Life Partner
NEW YORK, Sept. 20, 2024 /PRNewswire/ -- US-based EvolutionIQ, a global leader in claims guidance technology, has signed on as the Council of Australian Life Insurers (CALI)'s first Life Partner as part of its corporate partner program. The CALI Partner Program is designed to foster collaboration and create a connected ecosystem...
